2001

Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes

Top

K. Cusi, S. Cukier, R. A. DeFronzo, M. Torres, F. M. Puchulu and J. C. Pereira Redondo. Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2001;86:1410-1417. Vanadyl sulfate (VOSO4) is an oxidative form of vanadium that in vitro and in animal models of diabetes has been shown to reduce hyperglycemia and insulin resistance. Small clinical studies of 2- to 4-week duration in type 2 diabetes (T2DM) have led to inconsistent results.

Use of an Automated Device for Alternative Site Blood Glucose Monitoring

Top

Fineberg SE et al. Use of an automated device for alternative site blood glucose monitoring. Diabetes Care. 2001;24:1217-1220. To evaluate the accuracy, comfort, and ease of use of a new automated device for blood glucose monitoring using the arm as an alternative sampling site.

UKPDS 50: Risk Factors For Incidence and Progression of Retinopathy in Type II Diabetes Over 6 Years From Diagnosis

Top

Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: Risk Factors For Incidence and Progression of Retinopathy in Type II Diabetes Over 6 Years From Diagnosis. Diabetologia. 2001;44:156-163. To determine risk factors related to the incidence and progression of diabetic retinopathy over 6 years from diagnosis of Type II (non-insulin-dependent) diabetes mellitus.

Type 2 Diabetes Can Be Prevented by Dietary and Physical Activity Changes in Persons With Impaired Glucose Tolerance

Top

Tuomilehto J, Lindstram J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. Type 2 diabetes mellitus is increasingly common, primarily because of increases in the prevalence of a sedentary lifestyle and obesity. Whether type 2 diabetes can be prevented by interventions that affect the lifestyles of subjects at high risk for the disease is not known.

Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability

Top

Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability. Diabetes. 2001;50:1158-1165. We studied the effects of thiazolidinedione treatment (rosiglitazone 1 or 10 µmol · kg-1 · day-1 or darglitazone 1.3 µmol · kg-1 · day-1 for 3 weeks) on lipid metabolism in obese Zucker rats. In the basal 7-h fasted state, rosiglitazone (10 µmol · kg-1 · day-1) and darglitazone corrected the hypertriglyceridemia by increasing plasma triglyceride (TG) clearance and decreasing hepatic TG production, as assessed using Triton WR 1339.

The Relation of Markers of Inflammation to the Development of Glucose Disorders in the Elderly

Top

Barzilay JI, Abraham L, Heckbert SR, et al. The Relation of Markers of Inflammation to the Development of Glucose Disorders in the Elderly. Diabetes. 2001;50:2384-2389. Several studies suggest that inflammation plays a role in the pathogenesis of some glucose disorders in adults. We tested this hypothesis in a longitudinal cohort study of older individuals who had normal fasting glucose (FG) values at baseline.

The Better the Glycemic Control, the Less Likely it Is that Diabetic Patients Will Require Hospitalization for Acute Complications

Top

Menzin J, Langley-Hawthorne, Friedman M, et al. Potential short-term economic benefits of improved glycemic control. Diabetes Care. 2001;24:51-55. There are limited data relating glycemic control to medical costs among patients with diabetes. The goal of this study was to examine the potential impact of improved glycemic control on selected short-term complications of diabetes and associated costs in a managed care setting.

Suppression of Nuclear Factor-kappaB and Stimulation of Inhibitor kappaB by Troglitazone

Top

Ghanim H, Garg R, Aljada A, et al. Suppression of Nuclear Factor-B and Stimulation of Inhibitor B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese. Endocrinology. 2001;86:1306-1312. To elucidate whether troglitazone exerts an antiinflammatory effect in humans, in vivo, we investigated the suppression of nuclear factor kappaB (NFkappaB) in mononuclear cells (MNC) by this drug.

Subclincal States of Glucose Intolerance and Risk of Death in the U.S.

Top

Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclincal States of Glucose Intolerance and Risk of Death in the U.S. Diabetes Care. 2001;24:447-453. Although clinically evident type 2 diabetes is a well-established cause of mortality, less is known about subclinical states of glucose intolerance.

Study Finds Type 2 Diabetes Patients Have Increased Cardiovascular Burden Even With Good Glycemic Control

Top

Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL subfraction profile in type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract. 2001;51:107-114. To compare cardiovascular risk factors and LDL particle size in well-controlled Type 2 diabetes mellitus and normal subjects.

1 2 3 4 5 6 7 Next